Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in Iran by Mehrazmay, A. et al.
Hepatitis Monthly. 2013 August; 13(9): e10236. DOI: 10.5812/hepatmon.10236Published Online 2013 August 31. Research ArticleCost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
Alireza Mehrazmay 1, Seyed-Moayed Alavian 1, *, Maziar Moradi-Lakeh 2, Mahdi Mokhtari Payam 2, Amir Hashemi-Meshkini 3, 4, Bita Behnava 1, Seyyed Mohammad Miri 1, Pegah Karimi Elizeh 1, Seyed Vahid Tabatabaee 1, Maryam Keshvari 1, Kamran Bagheri Lankarani 5
1 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah Hospital, Tehran, IR Iran2 Department of Community Medicine, School of Medicine, Gastrointestinal and Liver Disease Research Center (GILDRC), Iran University of Medical Science, Tehran, IR Iran3 Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran4 Non-Communicable Disease Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran5 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
*Corresponding author: Seyed-Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah Hospital, Tehran, IR Iran. Tel: +98-2188067114, Fax: +98-2188067114, E-mail: alavian@thc.ir.
 Received: January 12, 2013; Revised: Jun 23, 2013; Accepted: July 15, 2013
Background: The prevalence of hepatitis C in Iran is 1% and 18% in general population and thalassemia patients respectively. The cost effectiveness analysis of adding Ribavirin to Peginterferon alfa-2a (PEG IFN alfa-2a) as a combination treatment strategy of chronic hepatitis C in thalassemia patients in comparison with monotherapy could help clinicians and policy makers to provide the best treatment for the patients.
Objectives: In this study we aimed to assess whether adding Ribavirin to PEG IFN alfa-2a is a cost effective strategy in different genotypes and different subgroups of 280 patients with chronic hepatitis C infection from the perspective of society in Iranian setting.
Patients and Methods: A cost effectiveness analysis including all costs and outcomes of treatments for chronic hepatitis C infected thalassemia major patients was conducted. We constructed a decision tree of treatment course in which a hypothetical cohort of 100 patients received “PEG IFN alfa-2a” or “Peg IFN alfa-2a plus Ribavirin.” The cost analysis was based on cost data for 2008 and we used 9300 Iranian Rials (IR Rial) as exchange rate declared by the Iranian Central Bank on that time to calculating costs by US Dollar (USD). To evaluate whether a strategy is cost effective, one time and three times of GDP per capita were used as threshold based on recommendation of the World Health Organization.
Results: The Incremental Cost Effectiveness Ratio (ICER) for combination therapy in genotype-1 and genotypes non-1 subgroups was 2,673 and 19,211 US dollars (USD) per one Sustain Virological Response (SVR), respectively. In low viral load and high viral load subgroups, the ICER was 5,233 and 14,976 USD per SVR, respectively. The calculated ICER for combination therapy in subgroup of patients with previously resistant to monotherapy was 13,006 USD per SVR. Combination therapy in previously resistant patients to combination therapy was a dominant strategy.
Conclusions: Adding low dose of Ribavirin to PEG IFN alfa-2a for treatment of chronic hepatitis C patients with genotype-1 was “highly cost effective” and in patients with low viral load and in previous monotherapy resistant patients was “cost effective.”
Keywords: Hepatitis C; PEG-Interferon Alfa-2a; Ribavirin; Cost-Benefit Analysis; Decision Support Techniques; Iran
Implication for health policy/practice/research/medical education:To guide policy makers and healthcare providers to make proper decision about these treatment strategies using the information about long term effec-tiveness and cost of them which are estimated by best available evidences and decision support models.Copyright © 2013, Kowsar Corp.; Licensee KowsarKowsar Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Li-cense (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. BackgroundInfection with hepatitis C virus (HCV) could end up with both acute and chronic hepatitis. Although acute infec-tion rarely causes hepatic failure but in 75 – 85 percent of cases it would be developed to chronic infection (1). Chronic HCV infection is usually slowly progressive and in most of patients may not result in clinically apparent liver disease; however, cirrhosis would occur in approxi-mately 20 – 30 percent of chronically infected patients 
over 20 – 30 years. The prevalence of hepatitis C varies between different regions but the World Health Organi-zation (WHO) has estimated the number of chronically infected hepatitis C patents around 150 million globally (2) which is consistent with other studies (3). Its preva-lence in Iran is less than 1% in general population (4). The prevalence of chronic hepatitis C infection in patients with beta thalassemia major is 18%, particularly because of blood transfusion before HCV serological testing (1, 5).Hepatitis C imposes considerable burden to the glob-
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al healthcare system in both acute and chronic forms. Global disability adjusted life years (DALYs) per 100,000 population in 2010 in comparison with 1990 has been estimated to have 44.4% growth in acute hepatitis C and also 21.3% and 1.9% growth in liver cancer and cirrhosis of the liver secondary to hepatitis C, respectively (6). This disease also reduces the quality of life in patients (7).Treatment with antiviral agents could eradicate the virus in the serum and hepatocytes. There are several regimens to treat chronic hepatitis C. Most recently, pe-gylated interferon (PEG-IFN) as a new generation IFN has shown improvement in response rate (8). Pegylation of IFN also extends the half-life of medicine from a few hours to several days, therefore the injection intervals is decreased from 3 times a week to only once a week (9) which could increase patients' compliance. Peginter-feron alfa-2a (PEG IFN alfa-2a) and peginterferon alfa-2b are the two types of PEG-IFN which are both approved by the US Food and Drug Administration (FDA) in treatment of hepatitis C which are different in some structural and pharmacokinetic characteristics (10) as well as effective-ness properties (11-15). Combination (or dual) therapy with PEG-IFN plus Ribavirin as an antiviral medicine has shown a promising effectiveness and also acceptable compliance in many studies (16), and also in Iranian pa-tients (17). In spite of availability and utilization of these medical treatments in Iran, there is not any published economic evaluation to compare these alternatives from Iranian perspective.
2. ObjectivesIn this study, we aimed to analyze the cost effectiveness of treatment with PEG IFN alfa-2a plus Ribavirin in com-parison with PEG IFN alfa-2a alone in hepatitis C infected thalassemia patients in Iran.
3. Patients and MethodsWe developed a decision analytic model to assess the cost and effectiveness of two available treatment strate-gies which are:1. Weekly subcutaneous injection of PEG IFN alfa-2a (Pegasys).2. Weekly subcutaneous injection of PEG IFN alfa-2a plus daily use of Ribavirin oral tablets (see Figure 1). The society was used as perspective of study. To develop decision tree model and all analysis, we used Tree Age Pro 2011 and Microsoft Excel 2007.
3.1. Patients and Treatment StrategiesThis model was designed and run for a hypothetical cohort of 100 thalassemia major patients with diagno-sis of chronic hepatitis C infection. Combination treat-ment strategy was defined as receiving 180 microgram
Figure 1. Decision Tree Indicating the Treatment Strategies Included in This Model
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(μg) of PEG IFN alfa-2a, subcutaneously once a week in combination with oral Ribavirin (600 – 800 mg per day based on patients’ hemoglobin level). In this strategy, patient with genotype-1 infection would be treated for 48 weeks and the other genotypes for 24 weeks. Monother-
apy strategy was defined as receiving 180 μg of PEG IFN alfa-2a for 48 weeks.A baseline viral load would be obtained from patients before beginning the treatment. In genotype-1 patients, the viral load test would be repeated after three months of therapy and compared with the baseline. In patients with complete Early Virological Response (EVR), indicat-ing no detectable HCV RNA, or partial EVR, indicating at least a two log reduction from baseline viral load, the treatment would be continued because there is a high probability of success at the end of treatment course. In other patients who do not achieve complete or partial EVR, treatment success is highly unlikely, therefore treat-ment would be stopped because of potential adverse ef-fects and costs and very low probability of success at the end. For partial responder patients, this procedure would be repeated again in sixth month and for patients with-out complete EVR at sixth month, treatment would be discontinued. Checking EVR would be less useful in geno-
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types non-1 due to the shorter treatment course and high-er response rates. So treatment of genotype-1 patients would be discontinued at third month for patients in the category of no response, and at sixth month for partial responders who do not achieve complete response. More details about the treatment strategies are represented elsewhere (18).
3.2. Data Sources for Decision Tree Model
3.2.1. Effectiveness and Outcomes of InterestAll effectiveness and safety data including different probabilities were extracted from a domestic clinical trial, conducted in Baqiyatallah University of Medical Sci-ences in 2007 which was about combination treatment of HCV in 180 thalassemia major patients (18). We did not use any international evidence, mostly because of less similarity with real situation of Iranian setting of treat-ment. The time period of this model was until the end of follow up course, which was 72 weeks in most of the patients so the longer time side effects were not taken into account. In this study the patients were categorized regarding three parameters: HCV genotype (genotype-1 and non-1), previous treatment outcome (naïve, resis-tant to previous monotherapy and resistant to combina-tion therapy), and the basic viral load (low viral load (< 600,000 IU/mL) and high viral load (> 600,000IU/mL).Final outcome was divided into sustain responder (SVR+) and sustain nonresponder (SVR-). Sustain Virologi-cal Response (SVR) is defined as no detectable viral level (the absence of hepatitis C RNA) after six months from completion of therapy (success) (19), and Sustain nonre-sponder (failure) consist of five situations including re-sponse then relapse (detected HCV RNA after treatment course), withdrawal (stopped treatment due to adverse effects or no response), no response (positive HCV RNA in all duration of treatment course), breakthrough (re-lapsed before the end of treatment course), death (death during treatment course).As proportion of genotype-1 in naïve subgroup (no pre-vious treatment) was not similar to Iranian population, and both cost and effectiveness outcomes are strongly dependent to genotype distribution of patients, compar-ing these two strategies in this subgroup was not relevant and valuable, therefore we did not calculate and report cost effectiveness ratios for this subgroup. Patients with genotype-1 virus, who consist about 66% of these patients population in Iran, have a much lower probability of SVR than those patients with non-genotype-1 virus (20).
3.2.2. CostIn this model, only direct medical costs including medi-cation (pharmaceutical) costs, laboratory tests, costs of side effects treatment and physician visits were taken into account and direct non-medical costs, indirect costs 
and intangible costs were not included in our analysis. Costs of physician visit charges and laboratory tests were extracted from the annual report of Medical Council of Is-lamic Republic of Iran. Costs of medicines were extracted from the Ministry of Health annual report on pharma-ceutical market entitled “Amarnameh.” To include side effect costs into our analysis, we only took physician vis-its and major medical and laboratory tests into account and the pharmaceutical cost were ignored because their costs were not considerable. The cost analysis was based on cost data for 2008. We also used 9300 Iranian Rials (IR Rial) as exchange rate declared by the Iranian central bank on that time to calculate costs by US Dollar (USD). No discount rate was considered in the cost analysis of this study.Considering the genotype distribution of different sub-groups in the patients, the weighted mean cost for each subgroup and also weighted mean cost of 100 patients were calculated.
3.3. Cost Effectiveness RatiosTwo cost effectiveness ratios were calculated based on our decision tree: cost effectiveness ratio (CER) which means cost per one SVR and indicates superiority of one strategy to the other one for cost effectiveness; and in-cremental cost effectiveness ratio (ICER) which means cost per one more SVR. To evaluate whether one strategy with more cost and more effectiveness or with less cost and less effectiveness is cost effective, we compared the ICER with recommended threshold of the World Health Organization (WHO) for countries without any calculat-ed threshold. In this method, ICER has to be compared with one and three times of GDP per capita and if it was less than one time of GDP per capita, it would be “highly cost effective” and if it was between one time and three times of GDP per capita it would be “cost effective”, but if it was more than three times of GDP per capita, it is “non-cost effective” (21). 4,678 USD was used as GDP per capita of Iran in 2008 based on the World Bank reports. This recommendation of WHO about threshold is mostly for cost utility analysis with “cost per QALY gained” or “cost per DALY averted” as outcome but as there is not any threshold calculated or accepted for Iran, we used it as our threshold.
3.4. Sensitivity AnalysisA deterministic one-way sensitivity analysis was con-ducted to evaluate the sensitivity of the result to the changes in key input variables of the model. The con-sidered key variables in this study were SVR and Positive Predictive Value (PPV) of EVR for combination therapy. PPV of EVR is defined as the proportion of EVR patients (complete or partial) with treatment success at the end of study. PPV could be associated with several internal and external parameters including sensitivity and speci-ficity of laboratory tests, pretest probability, quality of 
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medicines, HCV genotype and patients characteristics. By considering the minimum domain of 95% confidence interval of SVR and PPV, the ICER and also CER would be calculated to see how much the results of our model is dependent to variability of key input parameters regard-ing their uncertainties.
4. Results
SVR and PPV were calculated for two treatment strate-gies which are showed in the Table 1. As seen in this table, PPV is clearly higher in combination therapy strategy for all subgroups. This means that higher percent of mono-therapy group patients, would not achieve SVR and high-er cost for each SVR would be imposed to healthcare sys-tem and patients. 
Table 1. The Comparison Between Combination and Monotherapy for EVR, PPV and SVR in Different Subgroups
Subgroup Strategy EVRa SVRa(95% CIa) PPVa(95% CI)
Genotype-1 PEG IFN alfa-2a 84.85 29.27% (15.34 – 43.20%) 39.29 (21.20-57.38)PEG IFN alfa-2a + RBVa 93.00 48.74% (39.72 – 57.76%) 59.14 (49.15-69.13)
Genotype non-1 PEG IFN alfa-2a 90.91 47.50% (32.02 – 62.98%) 53.33 (35.48-71.19)PEG IFN alfa-2a + RBV 96.97 54.43% (43.45 – 65.41) 59.38 (47.34-71.41)
Low Viral Load PEG IFN alfa-2a 84.21 39.13 (25.03 – 53.23) 40.63 (23.61 – 57.64)PEG IFN alfa-2a + RBV 96.88 54.87 (45.69 – 64.04) 60.22 (50.27 – 70.16)
High Viral Load PEG IFN alfa-2a 92.59 38.71 (21.56 – 55.86) 52.00 (32.42 – 71.58)PEG IFN alfa-2a + RBV 91.18 44.71 (34.14 – 55.28) 59.68 (47.47 – 71.89)
Naïve PEG IFN alfa-2a 91.43 41.86 (27.11 – 56.61) 50 ( 28.61 – 71.39)PEG IFN alfa-2a + RBV 95.92 49.18 (36.63 – 61.73) 57.45 (36.30 – 78.59)
Resistant to Previous 
Monotherapy
PEG IFN alfa-2a 85.71 41.67 (21.94 – 61.39) 55.56 (34.30 – 76.81)
PEG IFN alfa-2a + RBV 96.36 59.68 (47.47 – 71.89) 69.81 (57.45 – 82.17)
Resistant to Previous 
Combination Therapy
PEG IFN alfa-2a 57.14 21.43 (0 – 42.92) 12.5 (3.6 – 21.4)
PEG IFN alfa-2a + RBV 91.94 44.59 (33.27 – 55.9) 54.39 (40.98 – 67.80)a CI, Confidence Interval; EVR, Early Virological Response; PPV, Positive Predictive Value; RBV, Ribavirin; SVR, Sustain Virological Response
 Table 2 indicates the cost of different components of HCV treatment in thalassemia major patients in Iran. As it is shown, there is not any considerable difference in medication (pharmaceutical) costs between these two 
treatment strategies in Iran because Ribavirin is far less expensive than PEG IFN alfa-2a. 
Table 2. The Cost Components of HCV Infection Treatment in Thalassemia Major Which Are Included in the Analysis
Service Detail Cost (USDa)
Medication CostPegasys Injection Pegasys dose was 180 μg/week 290Ribavirin rid="">Tablet 200 mg Ribavirin dose for Hb < 10 and Hb > 10 was 600 mg/day and 800 mg/day, respectively 0.34
Visits And HospitalizationRoutine Visits Gastroenterologist (totally 16 times in treatment duration) 7.4Consult Visits Cardiologist, psychiatrist, ophthalmologist and etc. (for adverse effects) 7.4 (9.1 for psychia-trist)Hospitalization Due to sepsis, DKA, heart failure, severe depression, hepatic decom-pensation Mean cost: 215
Laboratory TestsEnrollment Tests Include CBC, TFT, LFT, biochemistry, hepatitis serology, liver biopsy, PCR, lipid profile, LDH, AFP and genotyping) 325.75Routine Safety Evaluation Tests CBC, LFT, Ferritin, TG, Cholesterol and FBS 8.3
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Occasionally Tests HCV viral load in third month and PCR in sixth and 12th months of treatment course and third and sixth months of follow up course 139.7
Thyroid function test (TFT) each 3 months 15CBC It was performed weekly until the third month, then 2 times per month until 12th month and monthly in follow up course for combi-nation therapy group.
0.6
Cost of Supportive Intervention 
for Adverse EffectsPacked Cell Monotherapy and combination therapy patients' need to packed cell was averagely 33 and 54 units respectively. 129a Abbreviations: USD, US Dollar
The outcomes of cost effectiveness analysis were calcu-lated for combination and monotherapy strategies in the time period of 72 weeks and are summarized in Table 3. 
Table 3. Costs, Effectiveness and Cost Effectiveness Indicators in Subgroups for Two Monotherapy and Combination Therapy Strat-egiesa
Subgroup Strategy SVRb(95%CI) Cost for 100 Pa-
tients (USD)
CERb(USDbper one 
SVR)
ICERb(USD per one 
more SVR)
Genotype-1 PEG IFN alfa-2a 29.27% (15.34 – 43.20%) 1,754,180 59,934 2,673PEG IFN alfa-2a + RBVb 48.74% (39.72 – 57.76%) 1,806,231 37,058
Genotype non-1 PEG IFN alfa-2a 47.50 (32.02 – 62.98) 1,171,742 24,668 19,210PEG IFN alfa-2a + RBV 54.43% (43.45 – 65.41) 1,304,872 23,973
Low viral load PEG IFN alfa-2a 39.13 (25.03 – 53.23) 1,536,399 39,263 5,233PEG IFN alfa-2a + RBV 54.87 (45.69 – 64.04) 1,618,766 29,503
High viral load PEG IFN alfa-2a 38.71 (21.56 – 55.86) 1,482,614 38,300 14,975PEG IFN alfa-2a + RBV 44.71 (34.14 – 55.28) 1,572,469 35,173
Naïvec PEG IFN alfa-2a 41.86 (27.11 – 56.61) 1,733,217 NA NAbPEG IFN alfa-2a + RBV 49.18 (36.63 – 61.73) 1,690,536 NA
Resistant to Previ-
ous Monotherapy
PEG IFN alfa-2a 41.67 (21.94 – 61.39) 1,683,906 40,413 13,005
PEG IFN alfa-2a + RBV 59.68 (47.47 – 71.89) 1,918,141 32,141
Resistant To Previ-
ous Combination 
Therapyd
PEG IFN alfa-2a 21.43 (-0.07 – 42.92) 1,939,034 NA NA
PEG IFN alfa-2a + RBV 44.59 (33.27 – 55.92) 1,807,838 NAa GDP per capita: 4,678 USD; 3 times of GDP per capita:14,034 USDb Abbreviations: CER, Cost Effectiveness Ratio; ICER, Incremental Cost Effectiveness Ratio; NA, Not Applicable; RBV, Ribavirin; SVR, Sustain Virological Response; USD: US Dollar.c In this subgroup, the proportion of genotype-1 was not similar to Iranian population so we did not report any ratio for themd In this subgroup, combination therapy was a dominant strategy (higher effectiveness with lower cost) so calculation of cost effectiveness ratios was not reported.
Patients with genotype-1: the CER for monotherapy and combination therapy was 59,934 and 37,058 USD per SVR, respectively. So combination therapy with PEG IFN alfa-2a 
and Ribavirin needed less cost to achieve SVR. The calcu-lated ICER for combination therapy was 2,673 USD per SVR that is less than GDP per capita. It means that, adding Rib-
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avirin to PEG IFN alfa-2a could be considered as “highly cost effective” strategy in genotype-1 patients.Patients with genotype non-1: CER for monotherapy and combination therapy was 24,668 and 23,973 USD per SVR, respectively. So combination therapy with PEG IFN alfa-2a and Ribavirin needed less cost to achieve SVR. But ICER for combination therapy was 19,210 USD per SVR which was higher than three times of GDP per capita implying that adding Ribavirin to PEG IFN alfa-2a does not seem to be a “cost effective” strategy for these genotypes in Iran.Low basic viral load: CER for monotherapy and combi-nation therapy was 39,263 and 29,503 USD per SVR, re-spectively. So combination therapy with PEG IFN alfa-2a and Ribavirin needed less cost to achieve SVR. The ICER for combination therapy was 5,233 USD per SVR that was lower than three times per capita GDP. So adding Ribavi-rin to PEG IFN alfa-2a could be “cost effective.”High basic viral load: CER for monotherapy and com-bination therapy was 38,300 and 35,173 USD per SVR, re-spectively. So combination therapy with PEG IFN alfa-2a and Ribavirin needed less cost to achieve SVR. But ICER for combination therapy was 14,975 USD per SVR which was higher than three times of GDP per capita so adding Ribavirin to PEG IFN alfa-2a could not be considered as a “cost effective strategy.”Naïve patients: In this subgroup, the proportion of gen-otype-1 patients in the sample was not similar to society so we could not compare two strategies because of differ-ent duration of treatment and useless result for policy 
makers in Iran.Resistant to previous monotherapy: CER for mono-therapy and combination therapy was 40,413 and 32,141 USD per SVR, respectively. So combination therapy with PEG IFN alfa-2a and Ribavirin needed less cost to achieve SVR. The ICER for combination therapy was 13,005 USD per SVR which was lower than three times per capita GDP so adding Ribavirin to PEG IFN alfa-2a in this category of patients is a “cost effective” strategy in Iran.Resistant to previous combination therapy: In this sub-group, combination therapy was a dominant strategy meaning that it had more effectiveness and less cost com-pared to monotherapy which did not need any economic evaluation.
4.1. Sensitivity AnalysisFor sensitivity analysis, we calculated the ICER with the minimum amount of SVR and PPV in their 95% confi-dence interval. In minimum amount of PPV, combination therapy in genotype non-1 would be dominated and ICER in all other groups would be higher than three times of GDP per capita. In minimum amount of SVR in 95% con-fidence interval, combination therapy in genotype non-1 and high viral load subgroups would be dominated and in all other subgroups ICER would be higher than three times of GDP per capita. In Table 4, the calculated CER and ICER with minimum amount of SVR and PPV in several subgroups are shown. 
Table 4. Sensitivity Analysis: Calculated CER and ICER by Minimum Domain of 95% Confidence Interval of PPV and SVRa
Subgroup Monotherapy Combination Therapy
CERb(USDbper 
SVR)
Minimum PPVbin 95%CI Minimum SVRbin 95%CI
CER (USD per SVR) ICERb(USD per one 
more SVR)
CER (USD per SVR) ICER (USD per one 
more SVR)
Genotype-1 59,934 39,523 316,773 45,473 497,982
Genotype non-1 24,668 28,428 Dominated 30,033 Dominated
Low Viral Load 39,263 33,239 860,725 35,427 1,255,309
High Viral Load 38,300 36,332 1,966,050 46,064 Dominated
Resistant to Previ-
ous Monotherapy
40,413 34,654 1,711,831 40,410 4,038,486
a GDP per capita: 4,678 USD; 3 times of GDP per capita:14,034 USD.b Abbreviations: CER, Cost Effectiveness Ratio; ICER, Incremental Cost Effectiveness Ratio; PPV, Positive Predictive Value; SVR, Sustain Virological Response; USD, US Dollar.
5. DiscussionThis study indicated that although in all subgroups, combination therapy was more effective than monother-apy, but combination therapy of HCV in thalassemia ma-jor patients could be considered as a “highly cost effec-tive” strategy only in genotype-1 patients and as a “cost effective” strategy in low basic viral load patients and also in patients with previous resistance to monothera-
py. It was shown that in patients with previous resistance to combination therapy, it is a dominant strategy to put them therapy again in comparison with monotherapy.The other studies comparing monotherapy and com-bination therapy regimens in hepatitis C patients have shown that combination therapy is the most cost effec-tive treatment in the patients with genotypes 2, and 3 and low viral load patients (21-24); however, our study indi-cated that in HCV infected thalassemia major patients it 
Mehrazmay A et al.
7Hepat Mon. 2013;13(9):e10236
was for the patients with genotype-1 and low viral load pa-tients and previous monotherapy resistant patients. One limitation of our study was that the proportion of geno-type-1 was not similar to HCV infected thalassemia major population of Iran in naïve subgroup; therefore we were not able to generalize the result of this study to Iranian setting whether combination therapy is cost effective in this subgroup. As this is an applied study to be used only by policy makers in Iran, we decided not to calculate and report the ICER for this subgroup.This analysis was based on the clinical trial evaluat-ing both monotherapy and combination therapy group with the same inclusion criteria. As the types and sever-ity of adverse events experienced by patients who were exposed to PEG IFN alfa-2a and Ribavirin might be var-ied, we tried to include consideration of adverse events which could be resulted from treatment in the analysis. Using clinical data from a domestic clinical trial could be considered as an advantage for this study because of more similarity with real setting of Iran, but has its own weaknesses. One limitation was that only one domestic clinical trial was found which was not multicenter, how-ever we tried to overcome this limitation by sensitivity analysis. The number of patients in this clinical trial was also another limitation especially when we categorized them into subgroups which caused relatively wide 95% confidence interval. Another limitation of this study was that we did not take patients' quality of life into consider-ation. In one study evaluating the effects of PEG IFN alfa-2a plus Ribavirin in patients with chronic hepatitis C on their quality of life, the results indicated that quality of life of these patients was significantly improved (25). Us-ing more comprehensive outcome of interest (i.e. quality adjusted life years (QALY) or disability adjusted life years (DALY)) could provide better understanding about differ-ent aspects of disease and treatment effects. Also using more complicated decision support models including Markov models which consider more details of disease could result in more accurate output for policy makers.This study was based on cost data of 2008, so consider-ing much market variability in the health sector of Iran in the last years, the results may not be easy to defend in 2013. However it is a challenge over economic evaluation studies in the countries with rapidly changing or unsta-ble economic situation.Although both medicines are available in Iran, this study is the first economic evaluation of two common treatment strategies for HCV infection in thalassemia patients. The results of this analysis could be used by policy makers in setting reimbursement strategies and guideline development. More analysis is suggested to be conducted by considering more domestic and also in-ternational evidences, using more complicated models and more comprehensive outcomes and perspective for more accurate results. This study indicated that adding low dose of Ribavirin to PEG IFN alfa-2a for treatment of 
chronic hepatitis C infection in thalassemia is highly cost effective in genotype-1 patients and also cost effective in patients with low viral load or with previous monothera-py resistance. But in patients with genotype non-1 or high viral load, adding Ribavirin to PEG IFN alfa-2a could not be considered as a cost effective strategy.
AcknowledgementsThis research was supported by a grant from Baqiyatal-lah University of Medical Sciences, Tehran, Iran. We grate-fully acknowledge them and all persons who helped us in this research.
Authors' ContributionMahdi Mokhtari Payam, Amir Hashemi Meshkini, Seyyed Mohammad Miri, Seyed Vahid Tabatabaee, Bita Behnava, Pegah Karimi Elizeh, Maryam Keshvari and Kamran Bagheri Lankarani contributed to analysis and interpretation of data, statistical and cost effectiveness analysis and critical revision of the article. Dr. Alireza Mehrazmay contributed to provision, collection and as-semblage of study data and writing the manuscript. Dr. Seyed Moayed Alavian contributed to critical revision and final approval of the study.
Financial DisclosureAuthors declare there was no financial disclosure in the current study.
Funding/SupportThis study was supported by the grant 141-2120-7 from the Baqiyatallah University of Medical Sciences, and by a teaching and research scholarship from the research cen-ter for gastroenterology and liver disease (Dr. Alavian).
References1.       Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.2.       World Health Organization. . Hepatitis C. Fact sheet N°164. 2013; Available from: Available from: http://www.who.int/mediacen-tre/factsheets/fs164/en/.3.       Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin 
Infect Dis. 2012;55 Suppl 1:S10-5.4.       Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemi-ology of an Emerging Infection. Arch Iran Med. 2005;8(2):84-90.5.       Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vich-insky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93(8):1247-51.6.       Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and in-juries in 21 regions, 1990–2010: a systematic analysis for the Glob-al Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.7.       Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus in-fection causes a significant reduction in quality of life in the ab-sence of cirrhosis. Hepatology. 1998;27(1):209-12.8.       Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et 
Mehrazmay A et al.
Hepat Mon. 2013;13(9):e102368
al. Pegylated interferon-alpha2b: pharmacokinetics, pharmaco-dynamics, safety, and preliminary efficacy data. Hepatitis C Inter-vention Therapy Group. Clin Pharmacol Ther. 2000;68(5):556-67.9.       Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindol-lar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic pa-tients with chronic hepatitis C. Hepatology. 2001;33(2):433-8.10.       Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010;10(2):121-31.11.       Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effec-tive than peginterferon alfa-2b plus ribavirin for treating chron-ic hepatitis C virus infection. Gastroenterology. 2010;138(1):116-22.12.       Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176-84.13.       Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early viro-logic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14(10):721-9.14.       Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Sof-fredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108-15.15.       Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A ran-domised trial to compare the pharmacokinetic, pharmacody-namic, and antiviral effects of peginterferon alfa-2b and pegin-terferon alfa-2a in patients with chronic hepatitis C (COMPARE). 
J Hepatol. 2006;45(2):204-13.16.       Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 
1998;352(9138):1426-32.17.       Alavian SM, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadaniza-deh A, Abar K. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrho-sis in Iranian. Hepat Mon. 2004;4(7):53-8.18.       Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Kari-mi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012;12(6):372-81.19.       Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of pegin-terferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag 
Care Pharm. 2005;11(8):687-94.20.       Edejer TTT, World Health Organization. . Making Choices In Health: 
Who Guide To Cost Effectiveness Analysis. 2003.21.       Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;99(8):1490-6.22.       Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Hors-mans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg. 2007;70(2):177-87.23.       Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosen-berg W, et al. Cost effectiveness of interferon alpha or peginter-feron alpha with ribavirin for histologically mild chronic hepati-tis C. Gut. 2006;55(9):1332-8.24.       Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effective-ness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-37.25.       Liu J, Lin CS, Hu SH, Liang ML, Zhao ZX, Gao ZL. [Quality of life in patients with chronic hepatitis C after PEG-Interferon a-2a thera-py]. Zhonghua Gan Zang Bing Za Zhi. 2011;19(12):890-3.
